<?xml version="1.0" encoding="UTF-8"?>
<ref id="pmed.1002422.ref033">
 <label>33</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Grubb</surname>
   <given-names>IR</given-names>
  </name>, 
  <name>
   <surname>Beckham</surname>
   <given-names>SW</given-names>
  </name>, 
  <name>
   <surname>Kazatchkine</surname>
   <given-names>M</given-names>
  </name>, 
  <name>
   <surname>Thomas</surname>
   <given-names>RM</given-names>
  </name>, 
  <name>
   <surname>Albers</surname>
   <given-names>ER</given-names>
  </name>, 
  <name>
   <surname>Cabral</surname>
   <given-names>M</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Maximizing the benefits of antiretroviral therapy for key affected populations</article-title>. 
  <source>J Int AIDS Soc</source>. 
  <year>2014</year>;
  <volume>17</volume>:
  <fpage>19320</fpage>
  <comment>doi: 
   <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7448/IAS.17.1.19320" xmlns:xlink="http://www.w3.org/1999/xlink">10.7448/IAS.17.1.19320</ext-link>
  </comment>
  <?supplied-pmid 25043380?>
  <pub-id pub-id-type="pmid">25043380</pub-id>
 </mixed-citation>
</ref>
